Shunsuke Iwano/LinkedIn
Jun 23, 2026, 23:30
Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
Shunsuke Iwano, Representative Director and CEO, Head of Regulatory Affars Practice Japan at Eliquent Japan, Inc, shared on LinkedIn:
”PMDA has released a new Early Consideration on the clinical evaluation of Factor VIII and Factor IX products for pediatric congenital hemophilia in Japan.
Key takeaway: PMDA is introducing greater flexibility for pediatric rare disease development.
For hemophilia therapies:
- Patients aged 12 plus can generally be evaluated together with adults
- Under certain conditions, Japanese clinical trials in children under 12 may be waived by leveraging foreign pediatric data
This is an important step toward reducing development burden, minimizing unnecessary pediatric trials, and accelerating access to innovative therapies in Japan.
A meaningful signal that Japan is becoming more pragmatic in rare disease drug development.”
Stay updated with Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn RuksakulpiwatÖ‰ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin